MedTrace Logo

Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

NCT06326736 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-03-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of treating pancreatic cancer with surgery to remove cancerour tissue, followed by camrelizumab and a personalized cancer mRNA vaccines.

Conditions

Interventions

PROCEDURE

Surgery

Tumors of patients with pancreatic cancer must be radiographically resectable, and subjects with histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1) will be selected for neoantigen vaccine creation.

DRUG

Camrelizumab

Camrelizumab will be administered 6 weeks post-tumor resection.

BIOLOGICAL

SJ-Neo006

SJ-Neo006 will be prepared as personalized tumor Vaccines and administered 9 weeks post-tumor resection (+/- 2 weeks).

DRUG

Gemcitabine+Abraxane

Gemcitabine+Abraxane regimen will be administered 21 weeks post-tumor resection.

Sponsors & Collaborators

  • Jiangsu Synthgene Biotechnology Co.Ltd.

    collaborator UNKNOWN

  • Jinling Hospital, China

    lead OTHER

Principal Investigators

  • Xinbo Wang, MD · Jinling Hospital, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-30
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06326736 on ClinicalTrials.gov